Table 1.
Baseline patients’ characteristics.
| Characteristics | Patients, N (%) |
|---|---|
| Number of patients | 73 (100.0%) |
| Age, N (%) | |
| Mean (SD) | 67.5 (9.5) |
| Male | 67.3 (10.0) |
| Female | 68 (8.5) |
| <65 years old (%) | 33 (45.2%) |
| >65 years old (%) | 40 (54.8%) |
| Sex, N (%) | |
| Male | 52 (71.2%) |
| Female | 21 (28.8%) |
| ECOG-PS, N (%) | |
| 0–1 | 42 (57.5%) |
| ≥2 | 31 (42.5%) |
| Histology, N (%) | |
| Adenocarcinoma | 56 (76.7%) |
| Squamous cell carcinoma | 13 (17.8%) |
| Others | 4 (5.5%) |
| Smoking history, N (%) | |
| Never | 12 (16.4%) |
| Former/current | 56 (76.7%) |
| NA | 5 (6.9%) |
| Tumor site, N (%) | |
| Left | 35 (48.0%) |
| Right | 30 (41.0%) |
| Bilateral | 5 (6.9%) |
| NA | 3 (4.1%) |
| Metastases distribution, N (%) | |
| Bone | 24 (32.8%) |
| Nodes | 62 (84.9%) |
| CNS | 14 (19.2%) |
| Liver | 9 (12.3%) |
| Adrenal gland | 13 (17.8%) |
| Other | 14 (19.2%) |
| Therapy, N (%) | |
| TKIs, 19 (26.0%) | EGFR TKIs, 9 (12.3%) ALK TKIs, 5 (6.9%) ROS-1 TKIs, 2 (2.7%) BRAF + MEK TKIs, 3 (4.1%) |
| IO-based, 28 (38.3%) | Single-agent IO-based treatment, 13 (17.8%) IO-based treatment plus CT, 15 (20.5%) |
| CT, 26 (35.6%) | Cisplatin–gemcitabine, 2 (2.7%) Carboplatin–gemcitabine, 11 (15.1%) Cisplatin–pemetrexed, 5 (6.8%) Carboplatin–pemetrexed, 8 (11.0%) |